Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

• ClinicalTrials.gov Identifier: NCT01150045
• Recruitment Status: Unknown
• First Posted: June 24, 2010
• Results First Posted: August 6, 2021
• Last Update Posted: March 22, 2022
• Sponsor: Alliance for Clinical Trials in Oncology
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Alliance for Clinical Trials in Oncology

Tracking Information

• First Submitted Date: June 23, 2010
• First Posted Date: June 24, 2010
• Results First Submitted Date: May 27, 2021
• Results First Posted Date: August 6, 2021
• Last Update Posted Date: March 22, 2022
• Study Start Date: June 2010
• Actual Primary Completion Date: February 28, 2020 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: July 15, 2021)

Disease-free Survival [ Time Frame: At 3 years of follow-up ]

Disease-Free Survival (DFS) is defined as the time of randomization until documented progression or death from any cause. The endpoint of this trial is to compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive and disease free after 3 years are reported here. A log-rank test stratified with the stratification factors was used to compare disease-free survival (celecoxib vs placebo)

• Original Primary Outcome Measures (submitted: June 23, 2010): Disease-free survival

Current Secondary Outcome Measures (submitted: July 15, 2021)

Overall Survival [ Time Frame: up to 3 years from registration ]

Overall Survival (DFS) is defined as the time of randomization until documented death from any cause. The endpoint is to compare overall survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX; Arm A and Arm C) or standard chemotherapy (FOLFOX) with 5 years of celecoxib 400 mg daily (Arm B and Arm D). The percentage of patients who were alive after 3 years are reported here.

Original Secondary Outcome Measures (submitted: June 23, 2010)

• Recurrence-free survival
• Overall survival at 3 years
• Toxicity of celecoxib
• Cardiovascular-specific events
• Differences in toxicity, particularly cumulative peripheral neuropathy, of 6 vs 12 courses of FOLFOX

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
• Official Title: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

Brief Summary

PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib in treating colon cancer.

Detailed Description

OUTLINE: This is a multicenter study. Patients are stratified according to number of positive lymph nodes* (1-3 vs 4 or more) and concurrent regular low-dose of aspirin (yes vs no). Patients are randomized to 1 of 4 treatment arms. Please see the "Arms" section for more information. In all arms, treatment with celecoxib or placebo continues for 3 years in the absence of disease progression or unacceptable toxicity. Blood and tissue samples maybe collected for biomarker analysis and pharmacogenomic studies. The primary and secondary objectives for the research study are described below.

Primary objective:

1. To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only FOLFOX or standard chemotherapy FOLFOX with 3 years of celecoxib 400 mg daily.

Secondary objectives:

1. To contribute to an international prospective pooled analysis that will compare disease-free survival of patients with stage III colon cancer randomized to 6 treatments of adjuvant FOLFOX chemotherapy or 12 treatments of adjuvant FOLFOX chemotherapy.
2. To compare overall survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily.
3. To contribute to an international prospective pooled analysis that will compare overall survival of patients with stage III colon cancer randomized to 6 treatments of adjuvant FOLFOX chemotherapy or 12 treatments of adjuvant FOLFOX chemotherapy or 12 treatments of adjuvant FOLFOX chemotherapy.
4. To assess toxicities of celecoxib as maintenance adjuvant therapy in patients with stage III colon cancer.
5. To assess differences in cardiovascular-specific events with celecoxib versus placebo in a population of stage III colon cancer survivors.
6. To evaluate differences in toxicities, particularly cumulative peripheral neuropathy, for patients treated with 6 treatments of FOLFOX compared to those treated with 12 treatments of FOLFOX.

After completion of study therapy, patients are followed up every 6 months for up to 6 years.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
• Condition: Colorectal Cancer

Intervention

• Drug: celecoxib
  Patients receive celecoxib 400 mg administered by mouth, once daily.
• Drug: 5-fluorouracil
  Patients receive 400 mg/m^2 intravenous bolus then 2400 mg/m^2 continuous intravenous infusion over 46-48 hours.
• Other: placebo
  Patients receive placebo administered by mouth, once daily.
• Drug: oxaliplatin
  Patients receive 85 mg/m^2 intravenous over two hours.
• Drug: leucovorin
  Patients receive 400 mg/m^2 intravenous over two hours.

Study Arms

• Active Comparator: Arm A - FOLFOX and placebo (12 treatments)
  Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
  Interventions:

  • Drug: 5-fluorouracil
  • Other: placebo
  • Drug: oxaliplatin
  • Drug: leucovorin
• Experimental: Arm B - FOLFOX and celecoxib (12 treatments)
  Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
  Interventions:

  • Drug: celecoxib
  • Drug: 5-fluorouracil
  • Drug: oxaliplatin
  • Drug: leucovorin
• Active Comparator: Arm C - FOLFOX and placebo (6 treatments)
  Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
  Interventions:

  • Drug: 5-fluorouracil
  • Other: placebo
  • Drug: oxaliplatin
  • Drug: leucovorin
• Experimental: Arm D - FOLFOX and celecoxib (6 treatments)
  Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
  Interventions:

  • Drug: celecoxib
  • Drug: 5-fluorouracil
  • Drug: oxaliplatin
  • Drug: leucovorin

Publications *

• Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, Tan B, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF, Meyerhardt JA. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. J Clin Oncol. 2023 Feb 10;41(5):1079-1091. doi: 10.1200/JCO.22.01637. Epub 2022 Nov 11.
• Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, Andre T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2023 Feb 1;41(4):803-815. doi: 10.1200/JCO.21.02726. Epub 2022 Oct 28.
• Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021 Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454.

Recruitment Information

• Recruitment Status: Unknown status
• Actual Enrollment (submitted: July 15, 2021): 2527
• Original Estimated Enrollment (submitted: June 23, 2010): 2500
• Study Completion Date: Not Provided
• Actual Primary Completion Date: February 28, 2020 (Final data collection date for primary outcome measure)

Eligibility Criteria

1. Requirements for tumor parameters

   1. Histologically documented adenocarcinoma of the colon. The gross inferior (caudad) margin of the primary tumor must lie above the peritoneal reflection (i.e., patients with rectal cancer are not eligible). Surgeon confirmation that the entire tumor was above the peritoneal reflection is only required in cases where it is important to establish if the tumor is a rectal or colon primary.
   2. Tumors must have been completely resected. In patients with tumor adherent to adjacent structures, en bloc R0 resection must be documented in the operative report or otherwise confirmed by the surgeon. Near or positive radial margin are not exclusions as long as en bloc resection was performed. Positive proximal margin or distal margin is an exclusion.
   3. Node positive disease (N1 or N2) as designated in AJCC version 7. Either at least one pathologically confirmed positive lymph node or N1C (defined as tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastases). Patients with resected stage IV disease are not eligible.
   4. No evidence of residual involved lymph node disease or metastatic disease at the time of registration.
   5. Patients with synchronous colon cancers are eligible and staging for stratification will be based on higher N stage of the more advanced primary tumor. However, patients with synchronous colon and rectal primary tumors are not eligible.

2. NSAID use

   Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2 times per week (on average) or aspirin at more than 325 mg at least three times per week, on average. Low-dose aspirin not exceeding 100 mg/day is permitted. Patients who agree to stop regular NSAIDs or higher dose aspirin are eligible and no was out period is required.

3. Patient history

   1. No previous or concurrent malignancy, except treated basal cell or squamous cell cancer of skin, treated in situ cervical cancer, treated lobular or ductal carcinoma in situ in one breast, or any other cancer for which the patient has been disease-free for at least 5 years.
   2. No neurosensory or neuromotor toxicity ≥ grade 2 at the time of registration.
   3. No known allergy to platinum compounds.
   4. No prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or NSAIDs.
   5. No history of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years. Patients with ulceration, bleeding or perforation in the lower bowel are not excluded.
   6. No symptomatic pulmonary fibrosis or interstitial pneumonitis ≥ grade 2.

   7. No cardiac risk factors including:

      • Uncontrolled high blood pressure (systolic blood pressure > 150).
      • Unstable angina.
      • History of documented myocardial infarction or cerebrovascular accident.
      • New York Heart Association class III or IV heart failure.

4. Pregancy/nursing status

   Non-pregnant and not nursing. Men and women of childbearing potential must agree to employ adequate contraception for the duration of chemotherapy and for as many as 8 weeks after the completion of chemotherapy due to the unknown teratogenic effects of FOLFOX on the developing fetus.

5. Age and performance status

   1. ECOG performance status 0, 1 or 2.
   2. Age at least 18 years.

6. Required initial laboratory values

   1. Granulocytes ≥ 1,500/μL
   2. Platelet count ≥ 100,000/μL
   3. Creatinine ≤ 1.5 times upper limit of normal (ULN)
   4. Total Bilirubin ≤ 1.5 times ULN in the absence of Gilbert's disease
   5. Direct bilirubin ≤ 1.5 x upper limit of normal for patients with Gilbert's syndrome

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, Puerto Rico, United States

Administrative Information

• NCT Number: NCT01150045
• Other Study ID Numbers: CALGB-80702; U10CA031946 ( U.S. NIH Grant/Contract ); CALGB-80702; CDR0000675693 ( Registry Identifier: NCI Physician Data Query )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Alliance for Clinical Trials in Oncology
• Original Responsible Party: Monica M. Bertagnolli, Cancer and Leukemia Group B
• Current Study Sponsor: Alliance for Clinical Trials in Oncology
• Original Study Sponsor: Cancer and Leukemia Group B
• Collaborators: National Cancer Institute (NCI)

Investigators

• Study Chair: Jeffrey Meyerhardt, MD, MPH; Dana-Farber Cancer Institute

• PRS Account: Alliance for Clinical Trials in Oncology
• Verification Date: March 2022